Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST).
Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST).
复制标题
卡麦角林、喜得角和左旋多巴/卡比多巴的随机对照试点试验：洛杉矶可卡因快速药效筛选试验 (CREST)。
作者：
S. Shoptaw;D. Watson;C. Reiber;R. Rawson;Margaret A. Montgomery;M. D. Majewska;W. Ling
目的
本研究测试了三种多巴胺能药物对常见的不匹配安慰剂条件：喜得镇1 mg每日三次（n = 15）;左旋多巴/卡比多巴25/100 mg每日三次（n = 15）;卡麦角林0.5 mg每周（n = 15）;和安慰剂每日三次（n = 15）作为可卡因依赖的潜在药物治疗。
设计
四个平行组，Coconut快速疗效筛选试验（CREST）设计的特点是2周的基线期，然后随机分配到8周的药物治疗条件，包括每周1小时的认知行为药物咨询。在处死后4周进行安全性评价。
措施
结果包括尿液中测量的可卡因代谢物、药物使用的保留和自我报告、可卡因渴望、临床改善、情绪和HIV风险行为。
结果
分配接受卡麦角林治疗的受试者提供的可卡因代谢物阴性尿样（42.4%）多于分配接受安慰剂治疗的受试者（25.0%），在控制自我报告的可卡因使用基线差异后，差异具有统计学意义（F = 2.95，df = 3; P = 0.05）。当使用成瘾严重程度指数（ASI）就业子量表测量时，卡麦角林治疗的参与者表现出从基线到第8周相对于安慰剂的显著改善（总体变化= -0. 09，SD = 0. 10，t = 2. 36，P <0. 05）。安全性和不良事件指标显示，不同治疗条件下的投诉率和投诉类型相似。
结论
这些结果，结合卡麦角林在该人群中使用时的明显安全性，为进行更大规模的药物研究提供了经验支持。
AIM
This study tested three dopaminergic medications against a common unmatched placebo condition: hydergine 1 mg three times daily (n = 15); levodopa/carbidopa 25/100 mg three times daily (n = 15); cabergoline 0.5 mg per week (n = 15); and placebo three times daily (n = 15) as potential pharmacotherapies for cocaine dependence.
DESIGN
The four-parallel group, Cocaine Rapid Efficacy Screening Trial (CREST) design featured a 2-week baseline period followed by randomization to an 8-week medication condition that included 1 hour per week of cognitive behavioral drug counseling. A safety evaluation was conducted 4 weeks after termination.
MEASURES
Outcomes included cocaine metabolites measured in urine, retention and self-reports for drug use, cocaine craving, clinical improvement, mood and HIV risk behaviors.
RESULTS
Participants assigned to receive cabergoline provided more urine samples negative for cocaine metabolites (42.4%) than those assigned to receive placebo (25.0%), a statistically significant difference after controlling for baseline differences in self-reported cocaine use (F = 2.95, df = 3; P = 0.05). Cabergoline-treated participants demonstrated a significant improvement over placebo from baseline to week 8 when measured using the Addiction Severity Index (ASI) employment subscale (overall change = - 0.09, SD = 0.10, t = 2.36, P < 0.05). Safety and adverse event measures showed similar rates and types of complaints by treatment condition.
CONCLUSIONS
These results, combined with the apparent safety of cabergoline when used with this population, provide empirical support for conducting a larger study of the medication.
影响因子：
13.9
作者：
D. Self;Eric J. Nestler
通讯作者：
D. Self;Eric J. Nestler
影响因子：
5.5
作者：
JOHNSON, SW;NORTH, RA
通讯作者：
NORTH, RA
成瘾疾病药物治疗研究的整合：我们在哪里？
DOI：
10.1080/10550889709511145
发表时间：
1997
期刊：
Journal of addictive diseases : the official journal of the ASAM, American Society of Addiction Medicine.
影响因子：
--
作者：
Ling,W;Shoptaw,S
通讯作者：
Shoptaw,S